What is bioAffinity Tech's earnings per share (EPS)?

bioAffinity Tech (BIAF) reported diluted earnings per share of $-8.66 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

bioAffinity Tech Financials

BIAF

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows bioAffinity Tech (BIAF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 23/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

bioAffinity Tech has an operating margin of -171.6%, meaning the company retains $-172 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -95.6% the prior year.

Growth

bioAffinity Tech's revenue declined 34.2% year-over-year, from $9.4M to $6.2M. This contraction results in a growth score of 0/100.

Leverage

bioAffinity Tech carries a low D/E ratio of 0.51, meaning only $0.51 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

bioAffinity Tech's current ratio of 2.60 indicates adequate short-term liquidity, earning a score of 49/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While bioAffinity Tech generated -$9.3M in operating cash flow, capex of $61K consumed most of it, leaving -$9.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

bioAffinity Tech generates a -204.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -347.4% the prior year.

Piotroski F-Score Weak

3/9

bioAffinity Tech passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.63x

For every $1 of reported earnings, bioAffinity Tech generates $0.63 in operating cash flow (-$9.3M OCF vs -$14.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-238.3x

bioAffinity Tech earns $-238.3 in operating income for every $1 of interest expense (-$10.6M vs $44K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.2M

YoY-34.2%

bioAffinity Tech generated $6.2M in revenue in fiscal year 2025. This represents a decrease of 34.2% from the prior year.

EBITDA

-$10.1M

YoY-20.6%

bioAffinity Tech's EBITDA was -$10.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.6% from the prior year.

Net Income

-$14.9M

YoY-64.9%

bioAffinity Tech reported -$14.9M in net income in fiscal year 2025. This represents a decrease of 64.9% from the prior year.

EPS (Diluted)

$-8.66

bioAffinity Tech earned $-8.66 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$9.4M

YoY-27.9%

bioAffinity Tech generated -$9.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 27.9% from the prior year.

Cash & Debt

$6.4M

YoY+483.5%

bioAffinity Tech held $6.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

bioAffinity Tech had 4M shares outstanding in fiscal year 2025. This represents an increase of 766.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-171.6%

YoY-75.9pp

bioAffinity Tech's operating margin was -171.6% in fiscal year 2025, reflecting core business profitability. This is down 75.9 percentage points from the prior year.

Net Margin

-242.0%

YoY-145.4pp

bioAffinity Tech's net profit margin was -242.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 145.4 percentage points from the prior year.

Return on Equity

-204.9%

YoY+142.5pp

bioAffinity Tech's ROE was -204.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 142.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.4M

YoY-5.3%

bioAffinity Tech invested $1.4M in research and development in fiscal year 2025. This represents a decrease of 5.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$61K

YoY-23.4%

bioAffinity Tech invested $61K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 23.4% from the prior year.

BIAF Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$6.2M-34.2%	$9.4M+18.5%	$7.9M+164380.5%	$5K	N/A
Cost of Revenue	N/A	N/A	N/A	$467	N/A
Gross Profit	N/A	N/A	N/A	$4K	N/A
R&D Expenses	$1.4M-5.3%	$1.5M-0.5%	$1.5M+6.5%	$1.4M+36.8%	$1.0M
SG&A Expenses	$9.9M-0.3%	$9.9M+46.4%	$6.8M+173.7%	$2.5M+132.1%	$1.1M
Operating Income	-$10.6M-18.1%	-$9.0M-12.3%	-$8.0M-98.8%	-$4.0M-81.8%	-$2.2M
Interest Expense	$44K-52.0%	$92K+149.1%	$37K-98.5%	$2.5M+152.8%	$1.0M
Income Tax	$44K+278.0%	$12K-44.5%	$21K+753.7%	$2K+26.1%	$2K
Net Income	-$14.9M-64.9%	-$9.0M-13.9%	-$7.9M+2.7%	-$8.2M-28.9%	-$6.3M
EPS (Diluted)	$-8.66	$-22.50	$-0.91+49.7%	$-1.81	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.6M+10.1%	$1.4M+13.9%	$1.3M-31.5%	$1.9M-16.0%	$2.2M-6.1%	$2.4M-2.0%	$2.4M-0.4%	$2.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$374K+13.1%	$331K+6.2%	$311K-15.2%	$367K-6.0%	$391K+42.3%	$274K-31.8%	$402K+2.2%	$394K
SG&A Expenses	$3.0M+37.5%	$2.2M-0.2%	$2.2M-9.7%	$2.5M-16.0%	$2.9M+23.5%	$2.4M-4.4%	$2.5M+13.1%	$2.2M
Operating Income	-$3.1M-36.8%	-$2.3M+8.9%	-$2.5M+4.2%	-$2.6M+10.8%	-$2.9M-49.3%	-$2.0M+5.5%	-$2.1M-7.3%	-$1.9M
Interest Expense	$13K+143.9%	$5K-48.8%	$10K-32.5%	$15K-38.2%	$25K+15.8%	$22K-2.8%	$22K-5.5%	$24K
Income Tax	$3K0.0%	$3K-89.0%	$29K+233.3%	$9K	$0-100.0%	$3K-52.8%	$5K+47.6%	$4K
Net Income	-$3.1M+37.9%	-$5.1M-24.4%	-$4.1M-52.6%	-$2.7M+10.3%	-$3.0M-48.3%	-$2.0M+5.2%	-$2.1M-7.6%	-$2.0M
EPS (Diluted)	N/A	$-4.74	$-0.17-6.3%	$-0.16	N/A	$-4.84-2447.4%	$-0.19+5.0%	$-0.20

BIAF Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$11.0M+68.3%	$6.5M-20.8%	$8.2M-32.5%	$12.2M+738.2%	$1.5M
Current Assets	$7.6M+180.7%	$2.7M-32.2%	$4.0M-66.8%	$12.0M+731.7%	$1.4M
Cash & Equivalents	$6.4M+483.5%	$1.1M-60.8%	$2.8M-75.3%	$11.4M+738.9%	$1.4M
Inventory	$54K+94.0%	$28K+49.4%	$18K+233.6%	$6K	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.4M0.0%	$1.4M0.0%	$1.4M	N/A	N/A
Total Liabilities	$3.7M-5.8%	$3.9M+16.2%	$3.4M+195.6%	$1.1M-93.4%	$17.2M
Current Liabilities	$2.9M-6.4%	$3.1M+38.1%	$2.2M+97.4%	$1.1M-91.3%	$13.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.3M+179.7%	$2.6M-46.4%	$4.9M-56.0%	$11.0M+169.9%	-$15.8M
Retained Earnings	-$68.6M-27.8%	-$53.6M-20.3%	-$44.6M-21.6%	-$36.7M-28.6%	-$28.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$11.0M-5.1%	$11.5M+143.0%	$4.8M-14.4%	$5.5M-14.8%	$6.5M-0.6%	$6.6M-1.6%	$6.7M-17.3%	$8.0M
Current Assets	$7.6M-12.2%	$8.6M+416.1%	$1.7M-10.5%	$1.9M-30.8%	$2.7M+5.7%	$2.5M-4.9%	$2.7M-31.8%	$3.9M
Cash & Equivalents	$6.4M-15.9%	$7.7M+855.3%	$803K+80.5%	$445K-59.8%	$1.1M+46.1%	$757K-5.6%	$801K-67.3%	$2.5M
Inventory	$54K+52.0%	$35K-19.9%	$44K+13.4%	$39K+40.5%	$28K+8.9%	$25K-14.8%	$30K+213.8%	$9K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M
Total Liabilities	$3.7M+39.3%	$2.6M-61.6%	$6.9M+67.7%	$4.1M+5.0%	$3.9M+14.0%	$3.4M+6.4%	$3.2M+15.4%	$2.8M
Current Liabilities	$2.9M+23.2%	$2.4M-8.8%	$2.6M-24.2%	$3.4M+10.0%	$3.1M+24.6%	$2.5M+7.1%	$2.3M+31.3%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.3M-18.2%	$8.9M+516.7%	-$2.1M-248.4%	$1.4M-44.7%	$2.6M-16.6%	$3.1M-9.1%	$3.4M-34.7%	$5.3M
Retained Earnings	-$68.6M-4.8%	-$65.4M-8.4%	-$60.4M-7.2%	-$56.3M-5.0%	-$53.6M-5.9%	-$50.7M-4.1%	-$48.7M-4.5%	-$46.6M

BIAF Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$9.3M-28.4%	-$7.3M-20.3%	-$6.0M-48.3%	-$4.1M-98.7%	-$2.0M
Capital Expenditures	$61K-23.4%	$79K+245.3%	$23K-89.6%	$220K	N/A
Free Cash Flow	-$9.4M-27.9%	-$7.3M-21.2%	-$6.1M-41.2%	-$4.3M	N/A
Investing Cash Flow	-$61K+23.4%	-$79K+96.4%	-$2.2M-904.3%	-$220K	N/A
Financing Cash Flow	$14.7M+161.8%	$5.6M+1731.3%	-$345K-102.4%	$14.3M+331.2%	$3.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$2.6M-3.2%	-$2.5M+6.3%	-$2.6M-61.2%	-$1.6M+2.1%	-$1.7M+1.9%	-$1.7M-11.5%	-$1.5M+34.7%	-$2.3M
Capital Expenditures	$1+100.0%	-$4K-127.2%	$13K-73.6%	$51K+5078500.0%	$1-100.0%	$9K-66.7%	$28K-31.7%	$41K
Free Cash Flow	-$2.6M-3.0%	-$2.5M+6.6%	-$2.7M-57.2%	-$1.7M-0.9%	-$1.7M+2.4%	-$1.7M-10.1%	-$1.6M+34.6%	-$2.4M
Investing Cash Flow	-$1-100.0%	$4K+127.2%	-$13K+73.6%	-$51K-5078500.0%	-$1+100.0%	-$9K+66.7%	-$28K+31.7%	-$41K
Financing Cash Flow	$1.3M-85.7%	$9.3M+209.5%	$3.0M+192.5%	$1.0M-49.1%	$2.0M+21.0%	$1.7M+1936.6%	-$91K-104.5%	$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BIAF Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	90.3%	N/A
Operating Margin	-171.6%-75.9pp	-95.6%+5.3pp	-100.9%+83410.6pp	-83511.5%	N/A
Net Margin	-242.0%-145.4pp	-96.6%+3.9pp	-100.5%+169670.8pp	-169771.3%	N/A
Return on Equity	-204.9%+142.5pp	-347.4%-183.9pp	-163.5%-89.6pp	-73.8%	N/A
Return on Assets	-136.0%+2.7pp	-138.8%-42.2pp	-96.5%-29.6pp	-66.9%+368.4pp	-435.3%
Current Ratio	2.60+1.7	0.87-0.9	1.77-8.7	10.50+10.4	0.11
Debt-to-Equity	0.51-1.0	1.50+0.8	0.69+0.6	0.10+1.2	-1.09
FCF Margin	-152.4%-73.9pp	-78.4%-1.7pp	-76.7%+89259.8pp	-89336.5%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-196.9%-38.4pp	-158.6%+39.6pp	-198.2%-56.4pp	-141.7%-8.3pp	-133.5%-49.5pp	-84.0%+3.1pp	-87.1%-6.2pp	-80.8%
Net Margin	-197.0%+152.3pp	-349.3%-29.4pp	-319.9%-176.3pp	-143.5%-9.1pp	-134.4%-49.3pp	-85.1%+2.9pp	-88.0%-6.5pp	-81.5%
Return on Equity	-43.1%+13.6pp	-56.7%	N/A	-184.8%-70.8pp	-114.0%-49.9pp	-64.1%-2.6pp	-61.5%-24.2pp	-37.3%
Return on Assets	-28.6%+15.1pp	-43.8%+41.7pp	-85.5%-37.5pp	-48.0%-2.4pp	-45.6%-15.0pp	-30.5%+1.2pp	-31.7%-7.3pp	-24.4%
Current Ratio	2.60-1.0	3.65+3.0	0.64+0.1	0.55-0.3	0.87-0.2	1.02-0.1	1.15-1.1	2.22
Debt-to-Equity	0.51+0.2	0.30+3.5	-3.22-6.1	2.85+1.4	1.50+0.4	1.10+0.2	0.94+0.4	0.53
FCF Margin	-160.7%+11.1pp	-171.8%+37.8pp	-209.6%-118.3pp	-91.3%-15.3pp	-76.0%-2.9pp	-73.1%-8.0pp	-65.1%+34.1pp	-99.2%

Similar Companies

Mainz Biomed NV MYNZ

$10.6M

Advanced Biomed Inc. ADVB

$6.1M

XWELL Inc XWEL

$6.4M

Ispecimen Inc. ISPC

$1.4M

Check Cap CHEK

$9.4M

Frequently Asked Questions

What is bioAffinity Tech's annual revenue?

bioAffinity Tech (BIAF) reported $6.2M in total revenue for fiscal year 2025. This represents a -34.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is bioAffinity Tech's revenue growing?

bioAffinity Tech (BIAF) revenue declined by 34.2% year-over-year, from $9.4M to $6.2M in fiscal year 2025.

Is bioAffinity Tech profitable?

No, bioAffinity Tech (BIAF) reported a net income of -$14.9M in fiscal year 2025, with a net profit margin of -242.0%.

What is bioAffinity Tech's EBITDA?

bioAffinity Tech (BIAF) had EBITDA of -$10.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is bioAffinity Tech's operating margin?

bioAffinity Tech (BIAF) had an operating margin of -171.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is bioAffinity Tech's net profit margin?

bioAffinity Tech (BIAF) had a net profit margin of -242.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is bioAffinity Tech's return on equity (ROE)?

bioAffinity Tech (BIAF) has a return on equity of -204.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is bioAffinity Tech's free cash flow?

bioAffinity Tech (BIAF) generated -$9.4M in free cash flow during fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is bioAffinity Tech's operating cash flow?

bioAffinity Tech (BIAF) generated -$9.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are bioAffinity Tech's total assets?

bioAffinity Tech (BIAF) had $11.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are bioAffinity Tech's capital expenditures?

bioAffinity Tech (BIAF) invested $61K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does bioAffinity Tech spend on research and development?

bioAffinity Tech (BIAF) invested $1.4M in research and development during fiscal year 2025.

How many shares does bioAffinity Tech have outstanding?

bioAffinity Tech (BIAF) had 4M shares outstanding as of fiscal year 2025.

What is bioAffinity Tech's current ratio?

bioAffinity Tech (BIAF) had a current ratio of 2.60 as of fiscal year 2025, which is generally considered healthy.

What is bioAffinity Tech's debt-to-equity ratio?

bioAffinity Tech (BIAF) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is bioAffinity Tech's return on assets (ROA)?

bioAffinity Tech (BIAF) had a return on assets of -136.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is bioAffinity Tech's cash runway?

Based on fiscal year 2025 data, bioAffinity Tech (BIAF) had $6.4M in cash against an annual operating cash burn of $9.3M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is bioAffinity Tech's Piotroski F-Score?

bioAffinity Tech (BIAF) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are bioAffinity Tech's earnings high quality?

bioAffinity Tech (BIAF) has an earnings quality ratio of 0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can bioAffinity Tech cover its interest payments?

bioAffinity Tech (BIAF) has an interest coverage ratio of -238.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is bioAffinity Tech?

bioAffinity Tech (BIAF) scores 23 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.